IO360° Summit
Virtual
February 23–26, 2021
Immuno-Oncology 360° reports on the most current data and rapid advancements to help IO stakeholders:
- Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy
- Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof
- Partner to expand technology platforms to develop therapeutics at an accelerated rate
- Receive the latest pre-clinical, translational and clinical data from academia and industry
- Create and prioritize strategies targeted toward specific tumor types
- Identify and gain a greater understanding of what assets are available for potential combinations
- Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned
- Get key investor and analyst evaluations and insights on the IO landscape, challenges and what’s next
- Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more
- Obtain coverage on a wide range of emerging technologies
Keynotes:
- Padmanee Sharma, MD, PhD, MD Anderson Cancer Center
- Elizabeth Marion Jaffee, PhD, Johns Hopkins University
- Kole Roybal, PhD, University of California, San Francisco
- Lisa Butterfield, PhD, Parker Institute for Cancer Immunotherapy
- Andrew Baum, MD, Citi
Learn more about the upcoming IO360° Summit at www.io360summit.com
Receive a 10% discount with code ARM10
